Clinical Trial Update: A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma [Phase 2]

View source ↗

Summary

Phase II randomized trial comparing imatinib to interferon as adjuvant therapy for KIT-mutated melanoma; the document provides a trial status without results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Imatinib (imatinib)
• Interferon (interferon)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Melanoma | Phase 2 | Status: UNKNOWN